Development and validation of a MUC16 mutation-associated immune prognostic model for lung adenocarcinoma

Honggang Liu; Tao Xin; Hongtao Duan; Yuanyong Wang; Changjian Shao; Yifang Zhu; Jiansheng Wang; Jianjun He

doi:doi:10.18632/aging.204814

← Back

Research Paper Volume 15, Issue 12 pp 5650—5661

Development and validation of a MUC16 mutation-associated immune prognostic model for lung adenocarcinoma

Figure 8. Validation of the immune prognostic model (IPM) in clinical tissue samples by performing qRT-PCR assay in lung adenocarcinoma (LUAD) mucin 16 (MUC16) mutation tissue samples and LUAD non-MUC16 mutation tissue samples.